Advanced

CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment

Nopp, A.; Johansson, S. G. O.; Ankerst, Jaro LU ; Palmqvist, M. and Oman, H. (2007) In Allergy 62(10). p.1175-1181
Abstract
Background: Many clinical trials with omalizumab, Xolair, have been reported but the treatment period has always been short, i.e. < 12 months. After withdrawal, the clinical symptoms tend to return. A group of patients who stopped treatment after approx. 6 years allowed studies of the long-term effects of Xolair. Methods: The patient's cat or mite allergen sensitivity was quantitated as basophil allergen threshold sensitivity, CD-sens, and immunoglobulin E (IgE) and IgE- and IgG4-antibodies were determined before start and during treatment withdrawal. Asthma severity was evaluated from forced expiratory volume (FEV), peak expiratory flow (PEF) and a questionnaire. Results: At 6-14 months without Xolair 13 of the 18 cat and mite allergic... (More)
Background: Many clinical trials with omalizumab, Xolair, have been reported but the treatment period has always been short, i.e. < 12 months. After withdrawal, the clinical symptoms tend to return. A group of patients who stopped treatment after approx. 6 years allowed studies of the long-term effects of Xolair. Methods: The patient's cat or mite allergen sensitivity was quantitated as basophil allergen threshold sensitivity, CD-sens, and immunoglobulin E (IgE) and IgE- and IgG4-antibodies were determined before start and during treatment withdrawal. Asthma severity was evaluated from forced expiratory volume (FEV), peak expiratory flow (PEF) and a questionnaire. Results: At 6-14 months without Xolair 13 of the 18 cat and mite allergic asthmatics had either improved or remained the same as on treatment. Most of the patients were in a stable clinical condition reporting high quality of life, no increased nightly asthma attacks, no emergency visits as well as little or no increase in medication. The CD-sens to cat showed a peak 4 months after withdrawal but then decreased to levels below those of untreated patients with allergic asthma and at 12 months six of 14 had nonreactive basophils. Cat IgG4 antibody levels were higher than in cat allergics in general. Conclusion: Most of the patients 12-14 months had, after closing of 6-year Xolair treatment, a surprisingly mild asthma. Interestingly, and probably contributing to the clinical results, a downregulation of basophil, and presumably also mast cell, reactivity, was seen. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
immunoglobulin E, CD-sens, CD203c, CD63, omalizumab
in
Allergy
volume
62
issue
10
pages
1175 - 1181
publisher
Wiley-Blackwell
external identifiers
  • wos:000249275100012
  • scopus:34548479249
ISSN
1398-9995
DOI
10.1111/j.1398-9995.2007.01476.x
language
English
LU publication?
yes
id
16d2a5a8-69a9-4074-a665-44063edc38a7 (old id 686935)
date added to LUP
2007-12-17 16:08:07
date last changed
2017-10-29 04:24:47
@article{16d2a5a8-69a9-4074-a665-44063edc38a7,
  abstract     = {Background: Many clinical trials with omalizumab, Xolair, have been reported but the treatment period has always been short, i.e. &lt; 12 months. After withdrawal, the clinical symptoms tend to return. A group of patients who stopped treatment after approx. 6 years allowed studies of the long-term effects of Xolair. Methods: The patient's cat or mite allergen sensitivity was quantitated as basophil allergen threshold sensitivity, CD-sens, and immunoglobulin E (IgE) and IgE- and IgG4-antibodies were determined before start and during treatment withdrawal. Asthma severity was evaluated from forced expiratory volume (FEV), peak expiratory flow (PEF) and a questionnaire. Results: At 6-14 months without Xolair 13 of the 18 cat and mite allergic asthmatics had either improved or remained the same as on treatment. Most of the patients were in a stable clinical condition reporting high quality of life, no increased nightly asthma attacks, no emergency visits as well as little or no increase in medication. The CD-sens to cat showed a peak 4 months after withdrawal but then decreased to levels below those of untreated patients with allergic asthma and at 12 months six of 14 had nonreactive basophils. Cat IgG4 antibody levels were higher than in cat allergics in general. Conclusion: Most of the patients 12-14 months had, after closing of 6-year Xolair treatment, a surprisingly mild asthma. Interestingly, and probably contributing to the clinical results, a downregulation of basophil, and presumably also mast cell, reactivity, was seen.},
  author       = {Nopp, A. and Johansson, S. G. O. and Ankerst, Jaro and Palmqvist, M. and Oman, H.},
  issn         = {1398-9995},
  keyword      = {immunoglobulin E,CD-sens,CD203c,CD63,omalizumab},
  language     = {eng},
  number       = {10},
  pages        = {1175--1181},
  publisher    = {Wiley-Blackwell},
  series       = {Allergy},
  title        = {CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment},
  url          = {http://dx.doi.org/10.1111/j.1398-9995.2007.01476.x},
  volume       = {62},
  year         = {2007},
}